Masimo Corp is a global medical technology company that specializes in non-invasive monitoring solutions for patients
The company is best known for its innovative pulse oximetry technology, which measures blood oxygen levels and vital signs in real-time, providing healthcare professionals with critical data to enhance patient care. Masimo's products are designed to improve patient outcomes and safety across a wide range of clinical settings, including hospitals, outpatient facilities, and home care environments. In addition, the company develops advanced monitoring devices and software that integrate with existing medical systems, thereby optimizing workflows and enhancing the overall efficiency of healthcare delivery.
These large-cap stocks were top performers last week. Heico, Xpeng, Li Auto, Lineage, Erie Indemnity, Lloyds, Unum, FICO, Masimo, Smith & Nephew, AB InBev, and Nutanix all saw significant gains.
Masimo (NASDAQMASI) today announced that its management will participate in the 46th Annual Raymond James Institutional Investor Conference on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQDXCM).
Shares of medical tech company Masimo (NASDAQMASI)
jumped 11.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which beat analysts' revenue and EPS expectations. Sales grew 9% year on year, fueled by broad based demand. In addition, its full-year EPS guidance outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid quarter.
Medical tech company Masimo (NASDAQMASI) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.4% year on year to $600.7 million. Its non-GAAP profit of $1.80 per share was 26.3% above analysts’ consensus estimates.
Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance.
Today the Board of Directors (the “Board”) of Masimo (NASDAQMASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer (“CEO”) of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo’s Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025.
Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance.
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) concerning whether the board breached its fiduciary duties to shareholders.
Masimo (NASDAQMASI) today announced that its management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Masimo Corporation (NasdaqGS: MASI).
